Lamotrigine in Bipolar I Disorder (Long-term Extension)

Phase 3, open-label, single-arm trial of lamotrigine in bipolar I disorder, sponsored by GSK. Primary endpoints: Number of Participants With Any Serious Adverse Event (SAE) and Any Non Serious Adverse Event at 54 weeks, Number of Participants With the Indicated Clinical Laboratory Test Values for ALP, ALT, AST, GGT, and LDH at 52 weeks and 11 more. Started May 2008; status: completed.